Michael Berard, MD
Internal Medicine · College Park, MDNPI 1366459877
Payments from drug & device makers
Across 73 payments — averaging $67.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- Novo Nordisk$736
- AbbVie$127
- Lilly USA, LLC$115
- Medtronic$101
- AstraZeneca$75
- plus $180 from 7 others
What the payments were for
- Consulting fees$3,53572%
- Food & beverage$1,37228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $3,572 |
| Novo Nordisk | 43 | $736 |
| AbbVie(2 entities) | 5 | $127 |
| Lilly USA, LLC | 6 | $115 |
| Medtronic | 2 | $101 |
| AstraZeneca | 3 | $75 |
| Sanofi-aventis U.S. LLC | 2 | $54 |
| Exact Sciences | 1 | $29 |
| Watermark Medical, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
How this compares
$4,907 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $154,455 |
| JardianceEmpagliflozin | 115 | $146,993 |
| XareltoRivaroxaban | 84 | $118,040 |
| EliquisApixaban | 82 | $110,304 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $54,795 |
| ForteoTeriparatide | 11 | $46,765 |
| TrulicityDulaglutide | 13 | $19,558 |
| SynjardyEmpagliflozin/Metformin Hcl | 20 | $18,578 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,349 |
| Atorvastatin Calcium | 954 | $15,498 |
| Victoza 3-PakLiraglutide | 12 | $15,345 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $13,912 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $12,201 |
| Lidocaine | 49 | $11,335 |
| MounjaroTirzepatide | 11 | $11,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $736 | $165,485120 claims |
| Lilly USA, LLCForteo, Trulicity, Mounjaro | $115 | $77,49235 claims |
| GSKAnoro Ellipta | $3,572 | $12,20120 claims |
| AstraZenecaSymbicort | $75 | $5,36121 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $11 | $4,62712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in College Park
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.